FDA Device Review Timing in 2026: What Device Companies and Investors Should Check

← Back to All Insights

Device companies build financing plans around FDA timelines, and investors price those plans. Several things changed at FDA between 2025 and 2026: staff cuts across HHS, a 43-day government shutdown, revised guidance, and the start of user-fee reauthorization. None of them makes a particular company's review slower by a predictable amount, but together they are a reason to check the timeline assumptions in a model against published data rather than against review goals alone.

Review Goals Are Not Review Times

Under the current user-fee agreement, MDUFA V (fiscal years 2023 through 2027), FDA's goals include a decision within 90 FDA days for 95% of 510(k) submissions, within 150 FDA days for De Novo requests, and within 180 FDA days for 90% of original PMAs. FDA days exclude time a submission is on hold while FDA waits for the sponsor to answer a request for additional information, and for a 510(k) the sponsor has up to 180 calendar days to respond. Calendar time from submission to decision is therefore longer than the goal, and it depends on how many information requests a submission draws.

FDA publishes actual performance. Its MDUFA quarterly performance dashboards on FDA-TRACK cover submission cohorts from fiscal year 2023 onward; as of June 2026 they ran through the second quarter of fiscal year 2026. For a timeline assumption, the useful figures are how a pathway's recent cohorts performed against the goal and how long decisions took in calendar terms.

What Changed in 2025 and 2026

Staff cuts

On April 1, 2025, HHS carried out a reduction in force that included about 3,500 FDA employees. HHS said reviewers and inspectors would not be cut, but the reductions reached support functions such as policy staff and the project managers who keep sponsors informed about the status of reviews.

The 2025 shutdown

During the lapse in appropriations that began October 1, 2025, FDA could not accept new device submissions that required a user fee, including 510(k), De Novo and PMA submissions; reviews already under way continued. The shutdown ended November 12, 2025, after 43 days. A company that planned to submit in that window started its review later than planned.

Revised guidance

In January 2026, FDA issued revised final guidance on clinical decision support software and on general wellness products, changing which software functions fall outside device oversight. A guidance change can move a product's regulatory path, and its timeline with it.

User-fee reauthorization

MDUFA V expires September 30, 2027. FDA and industry reached an agreement in principle on MDUFA VI, which would cover fiscal years 2028 through 2032; FDA announced the draft commitment letter in July 2026 and held a public meeting on August 5, 2026. Congress still has to reauthorize the program. The review goals in the draft are largely unchanged.

Where Timeline Risk Shows Up in a Company

• Submission quality: each request for additional information adds hold time that the review goal doesn't count
• Pathway fit: a weak 510(k) predicate can lead to a not-substantially-equivalent decision and a second submission
• Novelty: De Novo requests and PMAs carry more open questions than a 510(k) with a clear predicate
• FDA engagement: a Pre-Submission can surface disagreements before the formal submission
• Runway: whether the financing plan holds if a decision comes later than planned

Due Diligence Questions That Matter

• Does the company's financial model use MDUFA goal dates, or calendar time drawn from published performance data for its pathway?
• How much runway is left if the decision comes one or two information-request cycles later than planned?
• Has FDA weighed in on the pathway and data plan through a Pre-Submission?
• Is there a fallback if FDA disagrees with the pathway, such as a different predicate or a De Novo request?
• Is the go-to-market timeline set by clearance, or by coverage and payment decisions that come later?

What a Vantage Report Reads on Regulatory Timing

A Vantage report assembles a company's FDA record and the submissions and correspondence the company provides, alongside FDA's published performance data for the relevant pathway, and cites each item to its source. It shows where a timeline assumption rests on a review goal rather than on the record; it does not predict when FDA will decide.